Key result
The acute pressor effect of L-NAME (38 +/- 4 mm Hg increase in MAP) is mediated in part by cyclooxygenase-dependent products and endothelin, but not by the renin-angiotensin system.
Why the study?
What endogenous vasoactive systems mediate the pressor effect of acute L-NAME administration in anesthetized Wistar rats?
What endogenous vasoactive systems mediate the pressor effect of acute L-NAME administration in anesthetized Wistar rats?
Answers are grounded in this paper and cite their sources.
The acute pressor effect of L-NAME in rats is mediated partly by cyclooxygenase-dependent products and endothelin, but not by the renin-angiotensin system.
The contribution of the renin-angiotensin system (RAS) and various endogenous vasoconstrictors on the pressor response to acute N omega-nitro-L-arginine methyl ester (L-NAME) administration (200 micrograms/kg/min) was assessed in anesthetized Wistar rats. Activity of the endogenous RAS was suppressed either by chronic treatment by a nonpeptide angiotensin II (AII) receptor antagonist (losartan) or an angiotensin-converting enzyme inhibitor (ACEI: enalapril), DOCA-salt pretreatment (without previous uninephrectomy), and binephrectomy (36-40 hours before experiments). We also studied the influence of chronic dietary sodium restriction. The role of alpha 1-adrenoceptor activity, endothelin (ET), and eicosanoids was evaluated in rats pretreated by prazosin, phosphoramidon (a nonspecific blocker of the conversion of big ET to ET), indomethacin, and the thromboxane A2 (TXA2) prostaglandin H2 (PGH2)-receptor antagonist SQ 29548, respectively. Finally, we tested the influence of the calcium channel blocker nicardipine on the vasopressor effect of L-NAME. In nonpretreated animals, L-NAME infusion induced an increase in mean arterial pressure (MAP) of 38 +/- 4 mm Hg. Chronic suppression of the RAS by losartan, enalapril, or DOCA did not alter the response to L-NAME, but the effect of L-NAME was moderately blunted in binephrectomized rats. Moderate attenuation (approximately 25%) and to a similar extent of the pressor effect of L-NAME was afforded by the low-sodium diet, phosphoramidon, SQ 29548, and indomethacin, whereas nicardipine markedly blunted by 74% the effect of L-NAME. We conclude that the acute pressor effect of L-NAME is mediated (at least in part) by cyclooxygenase-dependent products (mainly TXA2) and ET, but not by the RAS.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Nafrialdi et al. (1994) studied this question. N omega-nitro-L-arginine methyl ester (L-NAME) vs. Various pretreatments (losartan, enalapril, DOCA-salt, binephrectomy, low-sodium diet, prazosin, phosphoramidon, indomethacin, SQ 29548, nicardipine) was evaluated on Increase in mean arterial pressure (MAP). The acute pressor effect of L-NAME (38 +/- 4 mm Hg increase in MAP) is mediated in part by cyclooxygenase-dependent products and endothelin, but not by the renin-angiotensin system.
Synapse has enriched 10 related papers. Consider them for comparative context: